Comparative Pharmacology
Head-to-head clinical analysis: CARDENE IN 0 86 SODIUM CHLORIDE IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE IN 0 86 SODIUM CHLORIDE IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced afterload.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Intravenous infusion: Initial dose 5 mg/hour, titrate by 2.5 mg/hour every 5 minutes as needed to maximum 15 mg/hour. For maintenance, reduce to 3 mg/hour after blood pressure controlled. Label strength: 0.1 mg/mL in 0.86% NaCl.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Terminal half-life 8.6 hours; in hepatic impairment, half-life may be prolonged up to 2-fold
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal (70-80% as metabolites, <1% unchanged), fecal (20-30%)
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte